
Abb Ltd
SIX:ABBN

Intrinsic Value
The intrinsic value of one
ABBN
stock under the Base Case scenario is
37.1
CHF.
Compared to the current market price of 45.07 CHF,
Abb Ltd
is
Overvalued by 18%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Abb Ltd
Fundamental Analysis


Revenue & Expenses Breakdown
Abb Ltd
Balance Sheet Decomposition
Abb Ltd
Current Assets | 22.1B |
Cash & Short-Term Investments | 6.5B |
Receivables | 8.8B |
Other Current Assets | 6.8B |
Non-Current Assets | 20.4B |
Long-Term Investments | 404m |
PP&E | 5.2B |
Intangibles | 12.3B |
Other Non-Current Assets | 2.6B |
Free Cash Flow Analysis
Abb Ltd
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Abb Ltd
Revenue
|
32.9B
USD
|
Cost of Revenue
|
-20.2B
USD
|
Gross Profit
|
12.7B
USD
|
Operating Expenses
|
-7.3B
USD
|
Operating Income
|
5.4B
USD
|
Other Expenses
|
-1.3B
USD
|
Net Income
|
4.1B
USD
|
ABBN Profitability Score
Profitability Due Diligence
Abb Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Score
Abb Ltd's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
ABBN Solvency Score
Solvency Due Diligence
Abb Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

Score
Abb Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABBN Price Targets Summary
Abb Ltd
According to Wall Street analysts, the average 1-year price target for
ABBN
is 49.39 CHF
with a low forecast of 38.38 CHF and a high forecast of 61.1 CHF.
Dividends
Current shareholder yield for ABBN is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ABBN
stock under the Base Case scenario is
37.1
CHF.
Compared to the current market price of 45.07 CHF,
Abb Ltd
is
Overvalued by 18%.